Medicare payment suspensions have become one of the most disruptive enforcement tools used by the Centers for Medicare and Medicaid Services (CMS). What was once a rarely used administrative remedy is now routinely deployed to halt payments while CMS and its contractors investigate billing activity. Clinical laboratories, particularly those performing molecular, genetic, and specialty testing, are being targeted at an unprecedented rate. However, even laboratories engaged in more “routine” tests are seeing an increase in suspensions.
Understanding why these suspensions occur and how they can be lifted is essential for laboratories operating in today’s regulatory environment.
What is a Medicare Payment Suspension?
A Medicare payment suspension is an action taken by CMS to temporarily withhold Medicare reimbursements to a provider or supplier. CMS may impose a suspension when it determines that a credible allegation of fraud exists or when it has reliable information that an overpayment has occurred or may occur. Importantly, CMS does not need to prove fraud before suspending payments. A credible allegation can be based on data analysis, audit findings, referrals from law enforcement, or even complaints.
Once imposed, a suspension can remain in place for many months or even years while an investigation proceeds. During that time, claims continue to be submitted, but payments are withheld, placing providers in financial limbo.
Why Laboratories are Being Targeted
Our analysis of enforcement trends and CMS data shows that laboratories have become a focal point for Medicare program integrity efforts for several reasons.
First, laboratory testing represents a significant portion of Medicare spending, particularly in areas such as genetic testing, toxicology, and molecular diagnostics. These services often carry high reimbursement rates and involve complex coverage rules, making them susceptible to billing errors and, in some cases, abuse.
Second, Medicare data shows that laboratory services have a high rate of improper payments. CMS has reported that a large percentage of laboratory claim errors stem from documentation and medical necessity deficiencies. This makes laboratories an easy target for data-driven enforcement algorithms used by Medicare contractors. Compounding the issue, many documentation errors stem from referring providers’ notes, which are outside the laboratories’ control.
Third, CMS and its Unified Program Integrity Contractors (UPIC) use advanced analytics to identify billing patterns that deviate from national or regional norms. Laboratories that show unusually high test volumes, atypical test combinations, or spikes in certain codes are frequently flagged. These flags often lead to L3[1] Explanation of Benefits (EOB) denials, which are a common precursor to payment suspensions.
Finally, CMS has expanded authority to suspend payments under the Affordable Care Act. That authority has made suspensions a preferred enforcement tool because it allows CMS to protect program funds while an investigation is ongoing, without having to meet the higher legal standards required for civil or criminal action.
Common Triggers for Laboratory Suspensions
Based on recent experience, payment suspensions in the laboratory sector most often arise from one or more of the following:
- Unusual billing patterns compared to peer laboratories
- High volumes of highly scrutinized tests (e.g., genetic or molecular assays)
- Patient or provider complaints
- Prior unsuccessful post-payment audits
- Referrals from CMS contractors or whistleblower complaints
These triggers do not mean that a laboratory has committed fraud. In many cases, they reflect data anomalies or documentation gaps that can be addressed with the proper legal and compliance response.
How to Rebut a Payment Suspension
Although payment suspensions are serious, they are not irreversible. A structured response that includes a thorough review of the suspension basis, supporting medical and billing records, and the applicable Medicare requirements can help position a laboratory to seek reinstatement of payments in appropriate cases.
It is crucial to note that these suspensions offer an opportunity for a rebuttal response. However, unlike the CMS appeals process, this rebuttal is typically the only opportunity to overturn the suspension, and the timeframe for submission is extremely limited. This requires acting quickly and efficiently, with a clear understanding of what information must be submitted on an expedited basis.
The first and most important step is early and comprehensive assessment. Every suspension notice contains clues as to why a CMS contractor took such a drastic action. A detailed review of billing data, claim samples, and medical records is necessary to understand the scope of the issue and to craft an effective response.
The second step is documentation and medical necessity reconstruction. A large percentage of laboratory suspensions are driven by inadequate documentation rather than improper testing. By assembling complete medical records, physician orders, and coverage determinations, many laboratories can demonstrate that their claims were medically necessary and compliant with Medicare rules. This may also include working with the referring provider who requested the tests in question.
The third step is regulatory and legal advocacy. CMS and its contractors do not always apply the regulations correctly. Payment suspensions can be challenged when CMS relies on flawed data, misinterprets coverage policies, or exceeds its statutory authority.
Fourth, laboratories must directly engage with CMS contractors, where possible. Strategic communications with program integrity units, including the submission of corrective action plans and compliance enhancements, can persuade CMS contractors that continued payment suspension is unnecessary.
Finally, laboratories must address the root causes that triggered the suspension. Strengthening compliance programs, revising billing practices, and implementing internal audits are often essential to convincing CMS that future risk has been mitigated.
How Frier Levitt Can Help
A Medicare payment suspension is rarely an isolated event. It is usually part of a larger enforcement process that may include audits, overpayment demands, and potential False Claims Act exposure. Mishandling the response can significantly increase legal and financial risk that extends far beyond administrative action.
Frier Levitt represents laboratories and healthcare providers nationwide in payment suspension matters, audits, and enforcement actions. Our attorneys understand both the regulatory framework and the operational realities of clinical laboratories. We use that experience to develop practical strategies that protect our clients, restore cash flow, and position them for long-term compliance.
In today’s enforcement climate, laboratories cannot afford to take a passive approach to Medicare payment suspensions. Prompt, informed legal action often makes the difference between prolonged financial harm and a successful resolution.
[1] https://www.frierlevitt.com/articles/l3-eob-denials-medicare-payment-suspensions/
